Researchers have been battling to find the cure for cancer since we began to understand what cancer really was. A cure is the ultimate goal, but most medical professionals and patients would be ecstatic even hearing about new treatments. Current cancer treatments often come rife with side effects so severe that many choose to forgo them altogether. Stopping the growth of malicious cancer cells is the main goal of treatment, and removing them altogether is even better. The problem is, this kind of treatment almost always causes damage to surrounding healthy cells.
A treatment that changes cancerous cells into healthy, supportive cells sounds ideal. Transforming malignant cells into antibodies that would attack remaining cancer cells sounds too good to be true. Thanks to a groundbreaking study by scientists at The Scripps Research Institute (TSRI), this new, powerful form of cancer therapy could really be on the horizon.
An Accidental Discovery
The laboratory team was working on therapies for certain immune cell or blood factor deficiencies when they noticed some unusual effects of antibodies on marrow cells. They had been searching for antibodies that activate growth-factor receptors on immature bone marrow cells, meaning the antibodies would be able to induce these cells to mature into specific blood cell types.
After successfully identifying a number of antibodies that activated the bone marrow cell-receptors this way, the researchers noticed that some of the antibodies were having unexpected effects on the cells. Some of them were maturing into cells that were radically different from what had been expected, such as neural cells. This got the team thinking, could this method be used to convert cancerous marrow cells (leukemia cells) into non-cancerous cells?
In the new study, Richard A. Lerner, institute professor and the Lita Annenberg Hazen professor of Immunochemistry at TSRI and senior investigator, teamed up with colleagues, including first author Kyungmoo Yea, an assistant professor of cellular and molecular biology at TSRI. They decided to test 20 of the recently discovered receptor-activating antibodies on acute myeloid leukemia cells taken from human patients. One of the antibodies ended up having an incredible impact on the leukemia cells.
Most acute myeloid leukemia cells have the thrombopoietin (TPO) receptor, a receptor the winning antibody selectively and potently activated in marrow cells. When the antibody was applied to healthy marrow cells, the cells matured into blood-platelet-producing cells (megakaryocytes). When applied to the acute myeloid leukemia cells, though, the antibody caused them to mature into dendritic cells, which are key support cells in the body’s immune system.
This alone would have been a success — the researchers had effectively transformed cancerous cells into non-cancerous, helpful immune system cells. The team pushed further, though, and found that with longer exposures to the antibodies and other regulated conditions, the dendritic cells matured even more. The final product was a group of cells that very closely resembled natural killer (NK) cells. One of the body’s rapid immune defenses, NK cells are capable of rapidly attacking potentially dangerous pathogens and tumors even if they don’t contain the biomarkers normally identified by other immune cells.
“That antibody could have turned those acute myeloid leukemia cells into a lot of other cell types, but somehow we were lucky enough to get NK cells,” Lerner said in a press release.
These induced NK cells possessed a few unique characteristics, observed by the team through electron microscopy. The cells possessed extending tendrils that had made their way through the outer membranes of closeby leukemia cells — the kind of cells they would still be, had they not been exposed to the antibody. In lab tests, the NK cells betrayed their former brethren at an impressive pace: a “modest” number of NK cells took out about 15 percent of the surrounding leukemic cell population in only 24 hours.
An interesting detail noted by the researchers is the purely fratricidal nature of the NK cells. They attacked only related leukemia cells, while unrelated breast cancer cells did not die off in large numbers when put into contact with the NK cells. The team is still unclear on why exactly the NK cells behave this way, but hypothesize that other, yet-to-be-discovered antibodies could be the key to turning other cancerous cell types into NK cells.
Lerner has named this type of therapy “fratricidins,” and pointed out that they would have several advantages. The antibodies would be clinically useful with little to no modification, and the high specificity of the NK cells would reduce the likelihood of damage to surrounding healthy cells. This would make fratricidins a possible treatment with much more tolerable effects than traditional treatments like chemotherapy.
On top of that, every cancer cell in a population is potentially convertible, so in a successful therapy the cancer-cell population might not just be reduced, but eliminated entirely.
The Latest on: Cancer Treatment Breakthrough
via Google News
The Latest on: Cancer Treatment Breakthrough
Breakthrough cancer drug, used to treat rare condition, offered at two metro cancer centers
on June 14, 2019 at 5:36 pm
OLATHE, Kan. -- They say they're breaking new ground in cancer treatment. One metro infusion center said its among the first to use a new drug, and its said to be easier and more effective for ... […]
‘Major breakthrough’: Doctors unveil revolutionary cancer treatment
on June 13, 2019 at 8:37 am
Oklahoma doctors on Wednesday unveiled what they call a revolutionary new treatment for cancer patients. The treatment harnesses the body’s own immune cells to fight tumors, and it will be offered ... […]
Iovance Biotherapeutics Is The Next Biotech Takeover Candidate For Its Breakthrough TILs Technology
on June 13, 2019 at 8:02 am
The treatment of early stage disease is ... the excellent efficacy shown in refractory advanced cervical cancer, FDA has awarded Breakthrough therapy, Fast track and Orphan drug designations ... […]
'Fired by a passion to defeat cancer': Grant affirms Roswell Park's elite status
on June 12, 2019 at 8:07 am
Cancer survivors sat in the front rows of a packed conference center to hear the announcement. Afterward, several of them circled a bell that rings on campus when a patient finishes treatment. ... […]
Why Genentech's new $90K cancer-fighting drug — its 6th drug approval in 6 months — is a breakthrough
on June 11, 2019 at 4:39 am
Two months ahead of a scheduled decision date, regulators Monday approved a cancer-fighting drug from Genentech Inc ... a program designed to quickly OK drugs targeting serious conditions without ... […]
Great News For Jews This Week: Cancer Breakthrough, Teen Holocaust Educator, And Neil Patrick Harris
on June 7, 2019 at 12:08 pm
Treatment: Dr. Talia Golan of Israel’s prestigious Sheba Medical Center reported promising results for a new cancer treatment in the New England Journal of Medicine this week. Golan treated ... […]
Breakthrough in breast cancer therapy set to benefit women in India, know why treatment costs loom large
on June 6, 2019 at 12:59 am
For those who are not yet convinced about the seriousness of these details, take a look at some of the facts pertaining to breast cancer, which is the most frequent cancer among women, according to ... […]
Weekly Cancer News: The Latest Developments in Cancer Research and Treatment for the Week of May 12
on June 5, 2019 at 1:13 pm
Sometimes it’s big — like word that a breakthrough drug has increased survival ... meta-analysis can provide new insights into optimizing adjuvant treatment of colorectal cancer," the authors wrote. ... […]
Breakthrough combination therapy extends lives of young women with breast cancer
on June 4, 2019 at 5:30 pm
A breakthrough combination treatment detailed in a UCLA-led study improves overall survival in young breast cancer patients who previously had limited care options. Seventy percent of young, ... […]
Biotech stocks jump after drugmakers show positive data for potential breakthroughs in cancer treatment
on June 3, 2019 at 7:18 pm
The sector was led by cancer drug company Mirati Therapeutics. Biotech stocks jumped Monday after pharmaceutical companies presented some positive drug trial results on experimental medicines that ... […]
via Bing News